News & Updates

In the treatment of genitourinary syndrome of menopause (GSM), the nonhormone alternative vaginal hyaluronic acid is equally efficacious as the treatment standard vaginal oestrogen, while being well-tolerated, as shown in a pilot study.

Exposure to GLP-1 receptor agonist (RA) treatment during early pregnancy does not appear to increase the risk of complications in pregnant women, as shown in a study presented at ESHRE 2024.

In the 3-year updated analysis of the phase III TOPAZ-1 study, the combination of durvalumab and gemcitabine-cisplatin (GC) chemotherapy continues to deliver an overall survival (OS) benefit in individuals with biliary tract cancer (BTC).

A more selective risk-based approach to an enoxaparin thromboprophylaxis protocol appears to reduce the incidence of wound hematomas without increasing the rates of postpartum venous thromboembolism (VTE), as shown in a retrospective study.

The use of oral corticosteroids for more than 90 days among individuals with atopic dermatitis (AD) appears to be associated with a slight increase in the risk of adverse events (AEs), according to a study.

The nalbuphine nasal spray Apain may be used as a safe and noninvasive alternative to intramuscular nalbuphine for the relief of severe pain in patients who underwent orthopaedic interventions and traumatological procedures, suggests a study.